Colt harnesses ADVA FSP 3000 for quantum-secured transport in live network trial
16.2.2021 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Colt Technology Services has successfully conducted a field trial of quantum-secured transport using its FSP 3000 platform with ConnectGuard™ Layer 1 encryption technology. The trial utilized quantum key distribution (QKD) to super-encrypt live data traffic, demonstrating how mission-critical services can be protected even against large-scale attacks. Conducted over Colt’s deployed metro network in Frankfurt, the demo shows how enterprise customers can achieve secure cloud access and robustly protect sensitive data in the long term. ADVA’s partner ID Quantique also played a key role in the trial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005179/en/
ADVA’s ConnectGuard™ technology helps Colt showcase the future of quantum-safe networking (Photo: Business Wire)
“With quantum computers on the horizon, it’s crucial to stay one step ahead of the hackers. This trial is a major step towards the next generation of cryptographic infrastructure and takes us closer to safeguarding our customers’ information from tomorrow’s threats,” said Oktay Tekin, director, sales engineers, DACH, Colt Technology Services. “Businesses across the world depend on the speed, reliability and robust security of our services to operate effectively and with complete peace of mind. By conducting this trial with ADVA to harness QKD technologies, we’re exploring how to protect against unprecedented challenges further down the line.”
Widely predicted to be vital to the future of network security, QKD offers the ultimate defense against eavesdropping attacks. Using the laws of physics to create tamper-proof encryption keys, it protects traffic from all threats, including data harvesting for future quantum hacking. Colt’s trial harnessed the ADVA FSP 3000, which receives quantum keys generated by ID Quantique’s QKD technology. The QKD provides quantum random bit strings. These keys are used as an additional entropy source for the ADVA encryption solution, operating at line speeds of 100Gbit/s. The solution is the first commercial high-speed optical networking product to feature a dedicated interface for quantum keys based on the ETSI key delivery standard.
“Our FSP 3000 ConnectGuard™ encryption solution ensures maximum security as well as high capacity and low latency. In recent years, it has won a fierce reputation for protecting service provider and enterprise networks across the globe. Now, this trial of QKD-secure transport is proving how vital our technology will be even in the post-quantum era,” commented Uli Schlegel, director, product line management, ADVA. “Colt’s trial shows that it’s now possible to secure high-speed connectivity over deployed operational networks against tomorrow’s quantum computer attacks. It’s a significant milestone for Colt’s enterprise customers. From sensitive financial information to valuable intellectual property, their data will soon be shielded from the cybercriminals of the future.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Colt
Colt strives to transform the way the world works through the power of connectivity - taking what’s always been in its DNA to enable customers’ success. The Colt IQ Network connects more than 900+ data centres and over 29,000 on net buildings across Europe, Asia and North America’s largest business hubs.
Colt understands today’s shifting connectivity requirements and provides agile, on-demand and secure high bandwidth networking and voice solutions to ensure enterprises can thrive. Customers include data-intensive organisations spanning over 210 cities in more than 30 countries. Colt is a recognised innovator and pioneer in Software Defined Networks (SDN) and Network Function Virtualisation (NFV). Privately owned, Colt is one of the most financially sound companies in the sector, and because of this, it’s able to put its customers’ needs at its core. For more information, please visit www.colt.net.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005179/en/
Contact information
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
